43.44

0.14% -0.06

Vera Therapeutics Inc (VERA)

Overview News Price History Option Chain Financials Discussions Forecast

Vera Therapeutics Inc stock is currently priced at $43.44, with a 24-hour trading volume of 580.07K. It has seen a -0.14% decreased in the last 24 hours and a +9.70% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $42.93 pivot point. If it approaches the $44.34 resistance level, significant changes may occur.

Previous Close:

$43.50

Open:

$44.96

24h Volume:

580.07K

Market Cap:

$2.37B

Revenue:

Net Income/Loss:

$-95.99M

P/E Ratio:

-12.93

EPS:

-3.36

Net Cash Flow:

$-92.18M

1W Performance:

+9.56%

1M Performance:

+9.70%

6M Performance:

+312.93%

1Y Performance:

+514.43%

1D Range:

$43.40

$45.48

52W Range:

$6.93

$50.78

Vera Therapeutics Inc Stock (VERA) Company Profile

Name

Vera Therapeutics Inc

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

650-770-0077

Address

170 Harbor Way, 3rd Floor, South San Francisco

Employee

Twitter

Next Earnings Date

2024-05-09

Latest SEC Filings

VERA's Discussions on Twitter

Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-25-24	Initiated	Oppenheimer	Outperform
Jan-08-24	Initiated	Cantor Fitzgerald	Overweight
Dec-18-23	Initiated	Raymond James	Outperform
Nov-10-23	Upgrade	Jefferies	Hold → Buy
Aug-16-23	Initiated	Guggenheim	Buy
Jan-04-23	Downgrade	Jefferies	Buy → Hold
Jan-04-23	Downgrade	Wedbush	Outperform → Neutral
Jul-12-22	Initiated	JP Morgan	Overweight
May-02-22	Initiated	H.C. Wainwright	Buy
Apr-19-22	Initiated	Wedbush	Outperform

View All

Vera Therapeutics Inc Stock (VERA) Latest News

Could This Stock Be the Next Biotech Buyout?

The Motley Fool

Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex

Zacks Investment Research

Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact

Benzinga

Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket

Benzinga

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire Inc.

Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference

GlobeNewswire Inc.

Vera Therapeutics Inc Stock (VERA) Financials Data

Vera Therapeutics Inc (VERA) Net Income 2024

VERA net income (TTM) was -$95.99 million for the quarter ending December 31, 2023, a -7.79% decrease year-over-year.

Vera Therapeutics Inc (VERA) Cash Flow 2024

VERA recorded a free cash flow (TTM) of -$92.18 million for the quarter ending December 31, 2023, a -36.25% decrease year-over-year.

Vera Therapeutics Inc (VERA) Earnings per Share 2024

VERA earnings per share (TTM) was -$2.29 for the quarter ending December 31, 2023, a +31.85% growth year-over-year.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.